-$0.04 Earnings Per Share Expected for Stealth BioTherapeutics Corp (NASDAQ:MITO) This Quarter
Equities research analysts expect that Stealth BioTherapeutics Corp (NASDAQ:MITO) will report earnings per share of ($0.04) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Stealth BioTherapeutics’ earnings. The business is scheduled to report its next quarterly earnings report on Wednesday, November 13th.
According to Zacks, analysts expect that Stealth BioTherapeutics will report full year earnings of ($0.30) per share for the current year, with EPS estimates ranging from ($0.34) to ($0.25). For the next financial year, analysts forecast that the company will report earnings of ($0.20) per share, with EPS estimates ranging from ($0.26) to ($0.13). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Stealth BioTherapeutics.
Stealth BioTherapeutics (NASDAQ:MITO) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04.
MITO traded up $0.04 during trading hours on Thursday, reaching $6.47. The company’s stock had a trading volume of 2,700 shares, compared to its average volume of 21,879. The stock has a market cap of $230.15 million and a PE ratio of -4.59. The business’s 50-day moving average is $6.42 and its 200-day moving average is $10.55. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.13 and a quick ratio of 2.13. Stealth BioTherapeutics has a fifty-two week low of $4.97 and a fifty-two week high of $20.99.
Stealth BioTherapeutics Company Profile
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Further Reading: What is systematic risk?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.